HC Wainwright Trims DBV Technologies (NASDAQ:DBVT) Target Price to $5.00

DBV Technologies (NASDAQ:DBVT) had its target price dropped by stock analysts at HC Wainwright from $10.00 to $5.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, StockNews.com started coverage on shares of DBV Technologies in a research report on Monday. They issued a “hold” rating for the company.

DBV Technologies Trading Up 5.1 %

Shares of DBV Technologies stock traded up $0.04 during trading hours on Wednesday, reaching $0.72. 157,517 shares of the company’s stock were exchanged, compared to its average volume of 48,438. The company has a fifty day moving average of $0.75 and a 200-day moving average of $0.84. DBV Technologies has a 52-week low of $0.65 and a 52-week high of $2.37. The firm has a market capitalization of $137.90 million, a price-to-earnings ratio of -1.73 and a beta of 0.73.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. The company had revenue of $8.88 million for the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. During the same period last year, the business posted ($0.23) EPS. On average, equities research analysts anticipate that DBV Technologies will post -0.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cowen AND Company LLC acquired a new stake in shares of DBV Technologies during the 4th quarter worth approximately $49,000. Landscape Capital Management L.L.C. acquired a new position in shares of DBV Technologies during the third quarter worth approximately $94,000. Finally, Optiver Holding B.V. grew its holdings in DBV Technologies by 595.2% in the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after buying an additional 235,337 shares in the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.